Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorundrostat open-label extension in hypertension
NL-OMON60889Phase 3Active, not recruiting
- Sponsor
- Mineralys Therapeutics
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lorundrostat in hypertension (HTN) (3 arms), sponsored by Mineralys Therapeutics. Primary endpoints: Maintenance of antihypertensive effect, Randomized treatment withdrawal efficacy and 4 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
lorundrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NL-OMON60889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60889.